SecBot SecBot
Insider Cluster (4 insiders) ·Filed Jul 9, 2026

IONS

IONIS PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 4 insiders, $1.4M total
Actionable Insight • Neutral

These insider sales are immaterial and likely driven by routine portfolio diversification or tax planning. No actionable signal; focus on upcoming pipeline catalysts for IONS.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$58.25
T+0 close · Jul 9, 2026 · via day close
Latest settled
−25.32%
T+60 · $43.50
Vs SPY
−27.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $58.25entry
  2. T+1 · 4mo ago −2.93%α −2.15% · $56.54
  3. T+5 · 4mo ago −6.18%α −5.62% · $54.65
  4. T+20 · 3mo ago −2.90%α −5.33% · $56.56
  5. T+60 · 6w ago −25.32%α −27.96% · $43.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A cluster of insider sales at Ionis Pharmaceuticals (IONS) totaling $1.36M over a 7-day window, involving the Chief Scientific Officer, Chief Development Officer, and two directors. The total value represents only ~0.01% of the company's $14B market cap, making the sales immaterial and likely routine portfolio diversification or tax-related. No actionable signal for traders.

Key Financial Metrics

Direction
selling
Total Value
$1.4M
Insiders
4

Key Facts

  • Four insiders sold shares: EVP/CSO Bennett ($463K), Director Diaz ($864K), EVP/CDO Kordasiewicz ($31K), and Director Klein ($8K)
  • Total open-market proceeds: $1.36M
  • Sales represent ~0.01% of IONS' $14B market cap
  • No CEO or CFO participated in the sales
  • No other material corporate events (earnings, M&A, restructuring) accompanied this cluster

Financial Impact

Insider sales totaling $1.36M, representing 0.01% of $14B market cap, negligible relative to company size.

Risk Factors

  • No material risk identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (33 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IONS-1783639622793

Track record

26 reports on IONS

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
  4. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  5. Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  6. Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
  7. Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
  8. Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
  9. Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
  10. Jul 29, 202615w ago 8-K Neutral 5/10 Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026